H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

Group 1 - ImmunityBio, Inc. (NASDAQ:IBRX) is recognized as one of the 12 best NASDAQ penny stocks to buy according to hedge funds, with a Buy rating reiterated by H.C. Wainwright and a price target set at $8 [1][2][3] - The company announced promising developments with its drug ANKTIVA for treating advanced non-small cell lung cancer (NSCLC), showing that 60% of patients experienced reversal from lymphopenia and 80% maintained an absolute lymphocyte count (ALC) above 1,200 cells/uL [2][3] - The Phase 2 study results indicate significant improvements in survival rates among lymphopenia survivors, suggesting that ANKTIVA's immune reconstitution approach may have broader applications across various tumor types [3] Group 2 - ImmunityBio is a commercial-stage biotechnology firm focused on developing next-generation therapies that enhance the natural immune system to combat cancers and infectious diseases [4]